Aclaris Therapeutics, Inc.
ACRS
$1.13
$0.010.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -49.26% | 67.72% | 44.28% | 19.75% | -1.81% |
| Total Depreciation and Amortization | -6.49% | 8.12% | 16.65% | 15.37% | 8.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104,538.54% | -122.81% | -110.68% | -104.93% | -100.49% |
| Change in Net Operating Assets | 16.33% | 437.31% | -386.31% | 332.26% | 885.69% |
| Cash from Operations | 74.37% | 80.26% | 12.83% | 0.22% | -15.92% |
| Capital Expenditure | 90.76% | 42.24% | 37.82% | 10.36% | -116.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -246.54% | -36.08% | 412.79% | 302.04% | 259.17% |
| Cash from Investing | -250.95% | -35.94% | 459.35% | 338.60% | 266.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 189.61% | -96.62% | -96.68% | -62.07% | -62.09% |
| Repurchase of Common Stock | -300.98% | 25.49% | -1,427.27% | -481.48% | -200.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -515.86% | -- | -- | -- | -- |
| Cash from Financing | 179.10% | -99.98% | -100.39% | -63.41% | -63.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -183.53% | 138.08% | 77.59% | -205.98% | -130.11% |